Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DESF
- Development stage
- Phase 2
- Lead developer
- Aquestive Therapeutics
- Administration
- Sublingual
01
Overview
DESF is an investigational drug developed by Aquestive Therapeutics. It is being evaluated in a Phase 2 clinical trial for the treatment of Oral Allergy Syndrome (OAS). The drug is administered in the sublingual space, and the study aims to evaluate the pharmacokinetics and pharmacodynamics of epinephrine after single and repeat doses of DESF.
02
Targets
AR (Adrenergic receptors)
Beyond the preview
Go deeper on DESF.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DESF.